StratCann recently published an article, "International Cannabis Deals: Why Due Diligence Matters More Than Ever" by Jonathan Hiltz, that resonates far beyond its Canadian focus. Featuring insights from Export Development Canada, ConesCanada's Harrison Bard, and Chris Liddy of Solum Advisory, it dissects the perils of insufficient counterparty verification. For those of us navigating the UK medicinal cannabis import market, the parallels are stark and immediately applicable.

The Core Message: Verify, Don't Assume

The central tenet is clear: never assume legitimacy based on superficial appearances. Export Development Canada (EDC) guidance advocates for rigorous verification of a counterparty's legal registration, ownership, financial history, and the authority of individuals representing the entity. A polished website or impressive pitch deck is no substitute for hard data.

Chris Liddy's contribution to the article is particularly insightful, transforming abstract 'gut feelings' into actionable operational checks. Three of his points warrant specific attention for UK operators.

Identifying Red Flags in International Deals

Firstly, consider the nature of the approach itself. Be wary of deals that aggressively seek you out, demand rapid progression, offer unusually low pricing or guaranteed volumes, or promise expedited regulatory approvals in notoriously slow markets. Genuine buyers in regulated medical markets do not typically resort to such tactics.

Secondly, watch for opacity regarding the ultimate buyer. If early discussions obscure the importer of record behind vague references to 'partners' or 'the group', proceed with extreme caution. In a legitimate transaction, the licensed importer is never a mystery. UK operators who have wrestled with Home Office import licences or MHRA notifications understand precisely why: the importer of record is central to the entire process, bearing significant responsibility.

Thirdly, and perhaps most acutely, Liddy argues that anti-money laundering (AML) due diligence is not merely a banking or legal formality; it is fundamental commercial due diligence. He rightly points out that this industry too often neglects this, including within the UK. Firms may meticulously perfect their Good Distribution Practice (GDP) audit trails yet spend mere minutes vetting the origin of a counterparty's funds. This imbalance presents a significant and often underestimated risk.

Harrison Bard’s anecdote further reinforces this: despite extensive upfront documentation, the product ultimately delivered did not match the paperwork. This underscores that certifications are only valid when they correspond directly to the specific product in hand.

UK Applications: A Direct Translation

For UK operators, these insights translate directly. A Wholesale Distribution Authorisation (Human Use) (WDA(H)) holder importing CBPMs faces identical counterparty risks as an exporting entity. Key questions demand thorough answers:

  • Does the supplier possess the licences they claim, in the specified jurisdiction, verifyable through the actual regulator rather than a self-provided PDF?
  • Does their Good Manufacturing Practice (GMP) status cover the specific product and dosage form, extending beyond mere site certification?
  • Are the ownership structure and payment routes logical for the trade, or do they involve jurisdictions with no discernible connection?
  • Crucially, will the Home Office and MHRA paperwork withstand scrutiny once the consignment is real and situated in bonded storage?

We have encountered scenarios where attractive commercial terms masked negative answers to several of these questions. Walking away felt financially impactful at the time. However, the cost of proceeding, risking product loss, capital exposure, or even licence forfeiture, would have been far greater.

Liddy’s concluding observation should be a maxim for every business development team in this sector: organisations that embed robust due diligence now, proactively, before regulatory or banking pressures mandate it, are those most likely to achieve international scale and secure essential banking relationships. Compliance is not merely an overhead; it is a profound commercial advantage.

Actionable Due Diligence for UK Operators

If you are involved in importing, exporting, or brokering CBPMs, proportionate and documented due diligence is essential. Practical steps include:

  • Independent verification: Conduct registry checks and sanctions screening on all counterparties.
  • Licence validation: Rely on regulator-verified licences, not supplier-provided copies.
  • Beneficial ownership: Map beneficial ownership for all material entities.
  • Payment alignment: Ensure payment terms are consistent with the trade routes.
  • Ongoing monitoring: Implement periodic re-screening for the duration of the relationship.

None of these steps are complex, but they demand consistent execution.

Credit goes to StratCann for a genuinely impactful piece, and to Chris Liddy for elevating financial crime risk into a dialogue this industry has too long sidestepped. If your organisation requires assistance in developing a proportionate due diligence framework for international CBPM supply – covering supplier qualification, licence verification, or comprehensive counterparty risk assessment – please contact us at contact@medicexum.co.uk.

Source: https://stratcann.com/insight/international-cannabis-deals-why-due-diligence-matters-more-than-ever/